Did you receive a notice from Exforge Antitrust? Did you receive a mail about a class action settlement about Exforge Antitrust Lawsuit? This review will help you partake in the class action settlement after confirming the authenticity of the mail.
What Is Exforge Antitrust Class Action Settlement?
The Court has preliminarily approved proposed settlement in a lawsuit (the “Lawsuit”) brought by UFCW Local 1500 Welfare Fund and Law Enforcement Health Benefits, Inc. (the “End-Payor Plaintiffs” or “EPPs”)), on behalf themselves and similarly situated consumers and third-party payors who indirectly purchased, paid for, and/or reimbursed for some or all of the purchase price for brand or generic Exforge against Novartis Pharmaceuticals Corp. and Novartis AG (“Novartis”) and Par Pharmaceutical, Inc. (collectively, “Par,” and, together with Novartis, “Defendants”). The proposed settlement only concerns EPPs’ claims against Novartis.
What Is This Class Action All About?
The proposed settlement is with Novartis and will provide $30,000,000 in cash to resolve the End-Payor Class’s claims against Novartis (the “Settlement”).
Separate and apart from the proposed settlement with Novartis and in light of Par having filed for bankruptcy on August 16, 2022 in the United States District Court for the Southern District of New York, Case No. 22-22546, the EPPs have stipulated to dismiss with prejudice their claims against Par in this Lawsuit. This means that that the EPPs are no longer pursuing claims on behalf of the Class against Par. The EPPs’ dismissal of their claims against Par does not impact your rights under the proposed settlement with Novartis.
The Court has scheduled a hearing to decide on final approval of the settlement with Novartis, the plan for allocating the Settlement Fund to End-Payor Class Members, and Class Counsel’s request for settlement administration costs, attorneys’ fees, reimbursement of Class Counsel’s out-of-pocket expenses and costs, and service awards to EPPs.
That hearing is scheduled for October 3, 2023 before U.S. District Court Judge Alvin K. Hellerstein in Courtroom 14D of the United States District Court for the Southern District of New York, Daniel Patrick Moynihan U.S. Courthouse, 500 Pearl Street, New York, NY 10007.
Judge Alvin K. Hellerstein of the United States District Court for the Southern District of New York has determined that the Lawsuit can be a class action because it meets the requirements of Federal Rule of Civil Procedure 23, which governs class actions in federal courts
Who Is Eligible?
This settlement benefits all individuals who paid for or provided reimbursement for some or all of the purchase price of brand or generic Exforge (fixed combination of amlodipine and valsartan tablets).
This settlement covers entities and individuals who paid for the generic or brand-name blood pressure medication Exforge in certain states between September 21, 2012 and June 30, 2018
How To Be Part of This Settlement
To partake in this settlement, class member must submit a valid and timely claim on the settlement website by August 18, 2023. The deadline for exclusion and objection is August 18, 2023.
If you object to any part or all of the proposed settlement but you do not wish to exclude yourself from the Class, write to the Court about why you do not like the proposed settlement
You may choose to exclude yourself (i.e., “opt out”) from the Class. If you decide to exclude yourself, you will not be bound by any decision in this Lawsuit relating to Novartis.
What Is The Pay For This Settlement?
The pay for this settlement varies and the proof of purchase is not necessary.
Conclusion
As you submit your claim to the settlement website, just like Health care systems data breach class action settlement we have reviewed, you’re doing so under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. The final hearing is scheduled to October 3, 2023 at 10:30 AM EDT.
